Tang, Liang-Jie
Li, Gang
Eslam, Mohammed
Zhu, Pei-Wu
Chen, Sui-Dan
Leung, Howard Ho-Wai
Huang, Ou-Yang
Wong, Grace Lai-Hung
Zhou, Yu-Jie
Karsdal, Morten
Leeming, Diana Julie
Jiang, Pei
Wang, Cong
Yuan, Hai-Yang
Byrne, Christopher D.
Targher, Giovanni
George, Jacob
Wong, Vincent Wai-Sun
Zheng, Ming-Hua http://orcid.org/0000-0003-4984-2631
Funding for this research was provided by:
National Natural Science Foundation of China (82070588)
High Level Creative Talents from Department of Public Health in Zhejiang Province (S2032102600032)
Southampton NIHR Biomedical Research Centre (IS-BRC-20004)
Direct Grant from The Chinese University of Hong Kong (2020.045)
National Health and Medical Research Council of Australia (APP1053206, APP1196492, APP2001692, APP1107178, APP1108422)
Article History
Received: 27 June 2022
Accepted: 31 August 2022
First Online: 24 September 2022
Declarations
:
: Although the PRO-C3 ELISA test was carried out at Nordic Bioscience under a research collaboration, we confirm that cohort generation, research conceptualization, analysis, and manuscript drafting were carried out independently of the Nordic Bioscience team. ADAPT has not been developed as a proprietary test. The PRO-C3 ELISA test is not currently commercially available, but can be obtained as a Nordic Bioscience research test for research use only. Diana Julie Leeming and Morten Karsdal are employed by, and own stock at Nordic Bioscience. Grace Lai-Hung Wong and Vincent Wai-Sun Wong have served as speakers and/or consultants for Echosens. Liang-Jie Tang, Gang Li, Mohammed Eslam, Pei-Wu Zhu, Sui-Dan Chen, Howard Ho-Wai Leung, Ou-Yang Huang, Yu-Jie Zhou, Pei Jiang, Cong Wang, Hai-Yang Yuan, Christopher D. Byrne, Giovanni Targher, Jacob George and Ming-Hua Zheng have no conflicts of interest.
: The study was approved by the institutional review boards of both centres and all participants gave their written informed consent.